1. The future is now: Model‐based clinical trial design for Alzheimer's disease
- Author
-
Romero, K, Ito, K, Rogers, JA, Polhamus, D, Qiu, R, Stephenson, D, Mohs, R, Lalonde, R, Sinha, V, Wang, Y, Brown, D, Isaac, M, Vamvakas, S, Hemmings, R, Pani, L, Bain, LJ, Corrigan, B, and Diseases**, Alzheimer's Disease Neuroimaging Initiative for the Coalition Against Major
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biomedical and Clinical Sciences ,Neurosciences ,Dementia ,Clinical Research ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,Acquired Cognitive Impairment ,Brain Disorders ,Neurodegenerative ,Alzheimer's Disease ,Clinical Trials and Supportive Activities ,Aging ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Neurological ,Alzheimer Disease ,Clinical Trials as Topic ,Computer Simulation ,Drug Approval ,Europe ,Humans ,United States ,United States Food and Drug Administration ,Alzheimer's Disease Neuroimaging Initiative ,Coalition Against Major Diseases ,Pharmacology & Pharmacy ,Pharmacology and pharmaceutical sciences - Abstract
Failures in trials for Alzheimer's disease (AD) may be attributable to inadequate dosing, population selection, drug inefficacy, or insufficient design optimization. The Coalition Against Major Diseases (CAMD) was formed in 2008 to develop drug development tools (DDT) to expedite drug development for AD and Parkinson's disease. CAMD led a process that successfully advanced a clinical trial simulation (CTS) tool for AD through the formal regulatory review process at the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).
- Published
- 2015